

## Valsartan and Valsartan HCTZ Recall

**Summary:** The U.S. Food and Drug Administration (FDA) announced a voluntary recall of several medicines containing valsartan following detection of an impurity.

The FDA is alerting health care professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. This recall is due to an impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products. NDMA is classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.

For more information, including the specific products that are subject to the recall, please visit [www.fda.gov/Safety/Recalls/ucm613729.htm](http://www.fda.gov/Safety/Recalls/ucm613729.htm) or [www.fda.gov](http://www.fda.gov) → **Safety** (bottom of page) → **Recalls, Market Withdrawals, & Safety Alerts** → **7/13/2018 Major Pharmaceuticals Valsartan tablets**.

### Requested actions

- Please work with your patients to find a replacement for their prescription if their pharmacy does not have another manufacturer's valsartan product.
- To access to our searchable formulary for alternatives if needed, please go to [www.keystonefirstpa.com](http://www.keystonefirstpa.com) → **Providers** → **Pharmacy Services** → **Searchable formulary**.

**If you have any questions about this communication, please call Pharmacy Services at 1-800-588-6767.**